Table 3:

Adjusted odds of an inflammatory bowel disease patient having meningitis in the Quintiles IMS Legacy PharMetrics Adjudicated Claims Database between January 2001 and June 2016 in a nested case-control study

	aOR	95% CI
CCI# > 0	2.21	(1.76 – 2.77)
5-ASA*	0.40	(0.26 – 0.62)
Thiopurine	1.56	(0.88 – 2.76)
Anti-TNF#	0.79	(0.32 – 1.92)
Systemic Corticosteroids^	1.54	(0.99 – 2.40)
Region: East	Referent	Referent
Region: Midwest	0.68	(0.51 – 0.90)
Region: South	0.87	(0.67 – 1.12)
Region: West	0.64	(0.45 – 0.91)

Odds Ratios (ORs) are adjusted for type of IBD, current age, sex, comorbidity index, region and IBD medications

^#Deyo modification of the Charlson Comorbidity Index

^*5-Aminosalicylates: oral formulations only

^#TNF: Anti-Tumor Necrosis Factor-α

^{^}Defined as ≥ 2 week course of any oral systemic formulation